[
  {
    "ts": null,
    "headline": "Why investors should buy Amphenol & avoid Vertex Pharmaceuticals",
    "summary": "Zacks Investment Management senior client portfolio manager Brian Mulberry joins Market Domination with Josh Lipton to discuss why he recommends buying Amphenol (APH) and why he says investors should stay away from Vertex Pharmaceuticals (VRTX). To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=2a0ad29c8af28f95c3bd80fd769d89deb118870f29a1d089f2f718c7d4e50624",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755774017,
      "headline": "Why investors should buy Amphenol & avoid Vertex Pharmaceuticals",
      "id": 136467868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "APH",
      "source": "Yahoo",
      "summary": "Zacks Investment Management senior client portfolio manager Brian Mulberry joins Market Domination with Josh Lipton to discuss why he recommends buying Amphenol (APH) and why he says investors should stay away from Vertex Pharmaceuticals (VRTX). To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=2a0ad29c8af28f95c3bd80fd769d89deb118870f29a1d089f2f718c7d4e50624"
    }
  }
]